Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects With Chronic Hepatitis C Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs ACH 0137171 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease
- 05 Jun 2009 New trial record.